ANVISA and Butantan discuss anti-SARS-CoV-2 equine serum tests


Technicians from the National Health Surveillance Agency (ANVISA) and the Butantan Institute in Brasil met to
consider the requested authorization to research the use, in humans, of equine serum developed to combat COVID-
19, also known as anti-SARS-CoV-2 hyperimmune serum.

Butantan's team indicated that it will be making adjustments in its new version of the research protocol, in order to
cover important aspects of research that remain undefined. To date, no human studies have been conducted with
this serum, which require the authorization of ANVISA. At this point, the only available information concerns studies
with animals.



  • Share: